Our results highlight the clinical utility of plasma T790M ctDNA detection in guiding TKI therapies for EGFR mutant NSCLC patients, and support further validation of this approach in future prospective interventional multi-center clinical studies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.